Business Insider

FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

– Age-range for all EPIDIOLEX indications expanded to include patients one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine – ...
Business Insider

EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.

- Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies - - Comprehensive support program available ...
Morningstar

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American ...

DUBLIN, Dec. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) ...
CNN

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription ...
WebMD

Seizure Management: The Role of Epidiolex

How Does Epidiolex Work for Seizures? Seizures are caused by sudden electrical activity changes in the brain. These changes are temporary but result in changes in movement, behavior, sensation, or ...
Morningstar

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex ...

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy ...
Nasdaq

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed ...
WHNT

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

DUBLIN, Dec. 5, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex ®) Caregiver Survey that ...
Nasdaq

Jazz Pharma: Phase 3 Trial Of Epidiolex For Rare Epilepsies Fails To Meet Primary Endpoint

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ), in an update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies, said that the trial did not meet the primary efficacy ...
Benzinga.com

GW Pharma's Epidiolex Becomes First CBD To Get DEA Rescheduling

Amid the controversies surrounding the legalization of cannabis and associated products, gradual advancements have been made this year. As of Sept. 27, a specific type of cannabidiol, or CBD oil will ...